|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.53 USD | +1.44% |
|
+4.15% | -28.61% |
| 06-02 | Daxor Says Received US Patent for Remote Blood Volume Monitor Technology | MT |
| 04-26 | 5,061,267 Common Stock of Daxor Corporation are subject to a Lock-Up Agreement Ending on 27-APR-2026. | CI |
Main competitors
| P/E (Y) | Price to Book (Y) | PEG (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | 14.14x | 1.08x | -0.17x | 12.78x | - | 15.19x | 7.32% | 3.16B | |
| -27.36x | 0.54x | 0.03x | 8.43x | - | 20.37x | 16.22% | 2.89B | |
| Average | -6.61x | 0.81x | -0.07x | 10.61x | 17.78x | 11.77% | 3.03B | ||
| Weighted average by Cap. | -5.70x | 0.82x | -0.08x | 10.70x | 17.67x | 11.57% |
- Stock Market
- Stocks
- DXR Stock
- DXR Stock
- Sector Daxor Corporation
- Sector valuations
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
